PT-141 (Bremelanotide)

Overview

PT-141, known by its generic name bremelanotide and marketed as Vyleesi, is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors, primarily MC4R and MC3R. It is the first and only FDA-approved non-hormonal treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, having received approval in June 2019.

Bremelanotide has a molecular weight of 1,025.19 Da, a molecular formula of C₅₀H₆₈N₁₄O₁₀, and the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It was developed by Palatin Technologies and originally derived from the melanocortin peptide Melanotan II, which was itself based on the endogenous hormone alpha-melanocyte-stimulating hormone (alpha-MSH). Through structural optimization, bremelanotide was engineered to preserve melanocortin receptor binding while enhancing selectivity for the receptor subtypes most relevant to sexual function.

Mechanism of Action

Bremelanotide operates through a central nervous system-mediated mechanism that is fundamentally distinct from phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, which act peripherally on vascular smooth muscle.

Melanocortin Receptor Activation

Bremelanotide binds to and activates melanocortin 4 receptors (MC4R) in the hypothalamus, specifically within the paraventricular nucleus and medial preoptic area. These brain regions are integral to the neural circuitry governing sexual motivation and arousal.

Dopaminergic Pathway Modulation

Activation of hypothalamic MC4R by bremelanotide triggers a downstream signaling cascade that increases dopamine release in the medial preoptic area. Dopamine signaling in this region is associated with the “desire” component of sexual function, as opposed to the peripheral vascular mechanics of arousal. This mechanism targets the motivational and appetitive dimensions of sexual response.

Distinction from Hormonal Therapies

Unlike testosterone or estrogen-based interventions, bremelanotide does not modulate sex hormone levels. Its effects are mediated entirely through melanocortin-dopaminergic neurotransmission, making it a non-hormonal pharmacological approach to disorders of sexual desire.

Research Evidence

Phase 3 RECONNECT Trials

FDA approval of bremelanotide was based on two pivotal Phase 3 randomized, double-blind, placebo-controlled trials known as RECONNECT-1 (NCT02333344) and RECONNECT-2 (NCT02338960). These studies enrolled a combined total of approximately 1,267 premenopausal women diagnosed with HSDD.

Key findings from the RECONNECT program:

• Sexual desire: Bremelanotide 1.75 mg subcutaneous injection produced statistically significant improvements in desire scores as measured by the Female Sexual Function Index (FSFI) desire domain
• Sexual distress: Significant reductions in sexual distress were observed on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO), the co-primary endpoint
• Satisfying sexual events: A modest but statistically significant increase (0.5 events per month) was observed
• Patient-reported experience: Exit study interviews revealed that participants described increased feelings of sexual desire, physical arousal, and improvements in overall quality of sexual activities

Additional Clinical Research

Earlier clinical investigation also demonstrated efficacy in male populations. A study in men with sildenafil-resistant erectile dysfunction reported a 62% improvement rate in the PT-141 group compared to 21% with placebo, suggesting potential applications beyond the currently approved indication.

Long-term safety and efficacy data from an open-label extension study (published in Obstetrics and Gynecology, 2019) demonstrated maintained efficacy over 12 months with a consistent safety profile.

Regulatory History

Date	Event
Early 2000s	PT-141 investigated as intranasal formulation for erectile dysfunction
2007	Intranasal development halted due to blood pressure concerns
2014	Subcutaneous formulation entered Phase 3 trials for HSDD
June 2019	FDA approval of Vyleesi (bremelanotide) for HSDD in premenopausal women
2019–present	Post-marketing surveillance and additional research ongoing

Potential Applications

Based on published research and the approved indication:

• Hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA-approved indication)
• Male sexual dysfunction — early research showed efficacy in erectile dysfunction, though this is not an approved indication
• Melanocortin system research — bremelanotide serves as a pharmacological tool for understanding the role of melanocortin signaling in sexual behavior, appetite regulation, and inflammatory responses

Safety Considerations

Documented Adverse Effects

Data from the RECONNECT trials and post-marketing surveillance have identified the following adverse effect profile:

• Nausea: The most common adverse effect, reported in approximately 40% of patients, typically mild to moderate and diminishing with subsequent doses
• Flushing: Reported in approximately 20% of patients
• Headache: Reported in approximately 11% of patients
• Injection site reactions: Pain, erythema, or bruising at the subcutaneous injection site
• Transient blood pressure elevation: Bremelanotide can cause a small, transient increase in blood pressure (average increase of 2–3 mmHg systolic), which typically resolves within 12 hours
• Skin hyperpigmentation: Focal darkening at the injection site or in areas of existing pigmentation, related to melanocortin receptor activation in melanocytes

Contraindications and Precautions

• Uncontrolled hypertension or cardiovascular disease: Due to transient blood pressure effects, the FDA label includes warnings for patients with uncontrolled hypertension
• Hepatic impairment: Not recommended in patients with severe hepatic impairment
• Dosing limit: The FDA-approved labeling recommends no more than one dose per 24 hours and no more than 8 doses per month
• Drug interactions: Caution is advised with concomitant use of naltrexone, as bremelanotide may reduce the efficacy of opioid receptor antagonists

Pharmacokinetics

Bremelanotide has a plasma half-life of approximately 2.7 hours following subcutaneous administration. Peak plasma concentrations are reached approximately 1 hour post-injection, and the pharmacological effects on sexual desire are typically observed 45 minutes to several hours after administration.

Bremelanotide represents a significant advancement in the pharmacological understanding of sexual desire, demonstrating that central melanocortin-dopaminergic pathways can be therapeutically targeted. Its FDA approval provides a non-hormonal option for a condition that affects an estimated 6–10% of premenopausal women.